This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/news/528998-italy-vaccine-covid19-trial/
The article has changed 3 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial | Italian Covid-19 vaccine demonstrates safety and efficacy in phase-2 trial |
| (about 2 months later) | |
| An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. | An Italian firm has published promising results from its phase-two clinical trials, in which its Covid-19 vaccine induced an antibody response in 93% of volunteers three weeks after the first dose, reaching 99% after the second. |
| In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.” | In a press statement on Monday, Italian biotech company ReiThera said its candidate vaccine was well tolerated and “induces clear immune responses in trial subjects.” |
| The vaccine, called GRAd-COV2, generated an antibody response against the virus’s spike protein in over 93% of volunteers after the first dose, reaching 99% after the second. | The vaccine, called GRAd-COV2, generated an antibody response against the virus’s spike protein in over 93% of volunteers after the first dose, reaching 99% after the second. |
| The study involved 917 volunteers over the age of 18 at 24 centers across Italy. A quarter of volunteers were either over the age of 65 or had conditions associated with an increased risk of severe Covid-19. | The study involved 917 volunteers over the age of 18 at 24 centers across Italy. A quarter of volunteers were either over the age of 65 or had conditions associated with an increased risk of severe Covid-19. |
| “We are very excited about the preliminary phase two data,” said Roberto Camerini, ReiThera’s medical director, adding: “Our vaccine candidate confirmed its excellent safety and good immunogenicity profile in a large cohort. ReiThera reaffirms its commitment to the fight against Covid-19 in the face of pressing global demand for additional vaccines.” | “We are very excited about the preliminary phase two data,” said Roberto Camerini, ReiThera’s medical director, adding: “Our vaccine candidate confirmed its excellent safety and good immunogenicity profile in a large cohort. ReiThera reaffirms its commitment to the fight against Covid-19 in the face of pressing global demand for additional vaccines.” |
| While the company’s statement says that independent advisory boards recommend continuing the trial and advancing to phase three, ReiThera will need at least 60 million euros ($71 million) to fund the final-phase trial. In May, a state audit court rejected a plan that would pump public money into the firm. | While the company’s statement says that independent advisory boards recommend continuing the trial and advancing to phase three, ReiThera will need at least 60 million euros ($71 million) to fund the final-phase trial. In May, a state audit court rejected a plan that would pump public money into the firm. |
| ReiThera has already held early talks with the EU concerning a possible deal that would see Brussels diversify its supply of vaccines, which is currently highly reliant on shots provided by Pfizer and Moderna. | ReiThera has already held early talks with the EU concerning a possible deal that would see Brussels diversify its supply of vaccines, which is currently highly reliant on shots provided by Pfizer and Moderna. |
| Moderna’s CEO Stephane Bancel has previously warned that the world may have an oversupply of Covid-19 vaccines in 2022, as firms such as themselves hugely increase vaccine manufacturing capacity, and this could be challenging for developers. | Moderna’s CEO Stephane Bancel has previously warned that the world may have an oversupply of Covid-19 vaccines in 2022, as firms such as themselves hugely increase vaccine manufacturing capacity, and this could be challenging for developers. |
| If you like this story, share it with a friend! | If you like this story, share it with a friend! |